2024 marked another significant year in China’s intellectual property law space. Danlei Wu of Fangda Partners examines the key developments and the indicators for further developments in the year ahead
Chinese regulatory support to China originated-biopharma companies is going global. Wu Ting, partner of the Life Sciences and Healthcare Practice at Haiwen & Partners examines the implications
Simon Leung, Partner of Baker McKenzie, and Terry Xu, Senior Counsel at FenXun Partners, examine key regulatory shifts in 2024 and provide an outlook of potential regulatory trends for the banking and finance sector in 2025
China Law & Practice Awards 2024 sees a broad spectrum of law firms seize crown in individual practices. Fangda Partners and Clifford Chance win top accolades in the 18th annual CLP Awards.
In 2024, significant progress was made in the fields of legislation, merger control, administrative enforcement, and litigation under the PRC Anti-Monopoly Law. Huang Wei, Gao Chang, Zhu Fan and Ren Yuying of Tian Yuan Law Firm set out an overview of the major developments and key takeaways
Jianwei (Jerry) Fang, Chuchen (Julie) Hou and Jiaying (Kate) Jiang of Zhong Lun Law Firm discuss last year’s most significant legislative and judicial developments in civil and commercial dispute resolution in China
In 2024, the U.S. continued placing wide-ranging restrictions on Chinese interests. What made that year different was the impact those restrictions have on third countries. Charles Wu of Clyde & Co reviews the legislative changes, and offers practical insights into their potential impact with a focus on third countries, and the path forward in 2025
Dongping Liu and Xin Luo of Zhong Lun Law Firm analyze a significant set of new guidelines which are vital for foreign enterprises with a patent portfolio in China
